CELYAD ONCOLOGY (CYAD.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:CYAD - BE0974260896 - Common Stock
0.173 EUR
+0 (+1.17%)
Taking everything into account, CYAD scores 1 out of 10 in our fundamental rating. CYAD was compared to 86 industry peers in the Biotechnology industry. Both the profitability and financial health of CYAD have multiple concerns. CYAD is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CYAD has reported negative net income.
- CYAD had a negative operating cash flow in the past year.
- CYAD had negative earnings in each of the past 5 years.
- CYAD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -113.29%, CYAD is doing worse than 77.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.29% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-106.06%
ROA(5y)-75.47%
ROE(3y)-740.65%
ROE(5y)-467.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CYAD has a Gross Margin of 94.09%. This is amongst the best in the industry. CYAD outperforms 89.53% of its industry peers.
- In the last couple of years the Gross Margin of CYAD has remained more or less at the same level.
- The Profit Margin and Operating Margin are not available for CYAD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
- CYAD does not have a ROIC to compare to the WACC, probably because it is not profitable.
- CYAD has about the same amout of shares outstanding than it did 1 year ago.
- CYAD has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, CYAD has a worse debt to assets ratio.
2.2 Solvency
- CYAD has an Altman-Z score of -6.48. This is a bad value and indicates that CYAD is not financially healthy and even has some risk of bankruptcy.
- CYAD has a Altman-Z score of -6.48. This is in the lower half of the industry: CYAD underperforms 73.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.48 |
ROIC/WACCN/A
WACC7.12%
2.3 Liquidity
- A Current Ratio of 0.66 indicates that CYAD may have some problems paying its short term obligations.
- CYAD's Current ratio of 0.66 is on the low side compared to the rest of the industry. CYAD is outperformed by 80.23% of its industry peers.
- CYAD has a Quick Ratio of 0.66. This is a bad value and indicates that CYAD is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Quick ratio value of 0.59, CYAD is not doing good in the industry: 79.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.66 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
- CYAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.28%, which is quite impressive.
- CYAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 158.33%.
- The Revenue has been growing by 98.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)33.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.68%
Revenue 1Y (TTM)158.33%
Revenue growth 3YN/A
Revenue growth 5Y98.73%
Sales Q2Q%0%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CYAD. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- CYAD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CELYAD ONCOLOGY / CYAD.BR FAQ
What is the ChartMill fundamental rating of CELYAD ONCOLOGY (CYAD.BR) stock?
ChartMill assigns a fundamental rating of 1 / 10 to CYAD.BR.
What is the valuation status for CYAD stock?
ChartMill assigns a valuation rating of 0 / 10 to CELYAD ONCOLOGY (CYAD.BR). This can be considered as Overvalued.
What is the profitability of CYAD stock?
CELYAD ONCOLOGY (CYAD.BR) has a profitability rating of 1 / 10.